HUM Q2 Deep Dive: Margin Initiatives, Operational Progress, and Medicare Advantage Strategy

July 30, 2026 at 01:37 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

HUM Cover Image

Health insurance company Humana (NYSE: HUM) announced better-than-expected revenue in Q2 CY2026, with sales up 26.2% year on year to $40.89 billion. Its non-GAAP profit of $7.61 per share was 8.8% above analysts’ consensus estimates.

Is now the time to buy HUM? Find out in our full research report (it’s free for active Edge members).

Humana (HUM) Q2 CY2026 Highlights:

Revenue: $40.89 billion vs analyst estimates of $40.63 billion (26.2% year-on-year growth, 0.6% beat)
Adjusted EPS: $7.61 vs analyst estimates of $7.00 (8.8% beat)
Management reiterated its full-year Adjusted EPS guidance of $9 at the midpoint
Operating Margin: 3.3%, in line with the same quarter last year
Customers: 17.91 million, up from 17.71 million in the previous quarter
Market Capitalization: $43.87 billion

StockStory’s Take

Humana’s second quarter results reflected operational execution and continued focus on long-term strategic goals. Management highlighted that customer growth and operational cost reductions were central to the quarter’s performance, citing progress in clinical and operational initiatives. CEO James Rechtin pointed to tangible improvements in Stars program metrics and emphasized the impact of centralizing utilization management and expanding outsourcing for greater efficiency. CFO Celeste Mellet noted that medical and pharmacy cost trends remained in line with internal assumptions, with cost favorability concentrated among value-based care members. Management’s commentary avoided any shift to a negative or uncertain tone, instead focusing on how operational changes are driving intended outcomes.

Looking forward, Humana’s strategy is anchored on achieving a sustainable margin of at least 3% by 2028 and maintaining progress in its Stars program, which determines bonus payments from the Centers for Medicare & Medicaid Services (CMS). Rechtin explained that plan exits and benefit adjustments in 2027 will prioritize higher-performing Medicare Advantage products, with an emphasis on clinical excellence and operational discipline. Mellet underscored that contingency planning and prudent cost controls are embedded in future bids, while also acknowledging continued pressure from new drug costs. Management remains focused on reducing complexity, simplifying processes, and investing in technology to further improve margins and member experience.

Key Insights from Management’s Remarks

Management attributed Q2’s performance to operational streamlining, successful Stars program improvements, and continued member growth, while capital deployment and cost controls supported margin stability.

Operational centralization and efficiency: Humana advanced its operating model by centralizing functions like utilization management and expanding outsourcing in finance and HR, driving both general and administrative (G&A) cost savings and more consistent service for members and providers.
Stars program improvements: The company reported substantial operational progress in its Stars program, which measures care quality and impacts revenue from CMS. Management shared that internal metrics for quality and patient safety improved at a pace outpacing previous years, though they acknowledged uncertainty about the final CMS thresholds.
Plan mix and member retention: Adjustments to plan offerings and focus on higher-value Medicare Advantage plans contributed to improved profitability. The upcoming plan exits for 2027 are designed to protect and grow membership in core, higher-margin products while minimizing benefit disruption.
Value-based care performance: Humana saw cost trend favorability, particularly among members engaged with value-based providers who focus on preventative care and managing health outcomes. These relationships supported both cost containment and improved clinical results.
Capital allocation and divestitures: The company’s recent agreement to divest its minority stake in Gentiva for $900 million will be used to fund the MaxHealth acquisition. Additionally, Humana expanded its Medicaid presence with a new contract win in Illinois, supporting growth beyond its core Medicare Advantage base.

Drivers of Future Performance

Management’s outlook centers on sustaining margin expansion through operational streamlining, targeted plan adjustments, and continued investment in clinical excellence and technology.

Margin expansion through plan optimization: Management expects margin gains in 2027, primarily through a combination of benefit redesign, targeted plan exits, and continued focus on operational efficiency. These actions are aimed at shifting the business mix toward higher-margin Medicare Advantage products, while also managing medical and pharmacy cost trends.
Stars program and quality focus: The company believes that further operational improvements in the Stars program will drive bonus revenue and competitive positioning. While acknowledging some uncertainty around CMS thresholds, management remains focused on achieving a top quartile ranking, which directly impacts future profitability.
Investment in technology and simplification: Humana is prioritizing investments in automation, artificial intelligence, and process simplification to reduce costs and improve member experience. These initiatives are expected to deliver structural operational efficiencies and support margin expansion over the next several years.

Catalysts in Upcoming Quarters

In upcoming quarters, our analysts will closely monitor (1) the October release of CMS Stars ratings to validate whether operational improvements translate into higher bonus payments, (2) execution of the 2027 Medicare Advantage plan exits and the company’s ability to retain and recapture members, and (3) continued progress on cost reduction and process simplification initiatives. Developments in drug pricing trends and Medicaid expansion will also be important indicators for future performance.

Humana currently trades at $364.00, in line with $365.92 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	271.58	+36.08 (15.32%)
AAPL	308.91	-24.52 (-7.35%)
AMD	476.15	-9.24 (-1.90%)
BAC	61.95	+0.22 (0.36%)
GOOG	356.65	+22.97 (6.88%)
META	556.71	+17.68 (3.28%)
MSFT	464.72	+13.62 (3.02%)
NVDA	200.75	+5.71 (2.93%)
ORCL	129.87	+2.31 (1.81%)
TSLA	311.21	+2.36 (0.76%)

Get intelligentvalue.com

intelligentvalue.com

Safe & Secure

Fast Transfer

Flexible Payments